TG Therapeutics (TGTX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 11/100 (LOW), 57.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 22.67% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
- How TG’s MS Data Wave At MSToronto2026 At TG Therapeutics (TGTX) Has Changed Its Investment Story
- TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow
- TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
- TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share
- TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry
- TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Meta, Tesla, SpaceX Take Center Stage As Earnings Season Kicks Into High Gear. Everything You Need To Know.
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for TG Therapeutics.
Full TGTX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.